about
Current standards and new concepts in MRI and PET response assessment of antiangiogenic therapies in high-grade glioma patientsSchwannoma of the olfactory nerve. Report of two cases and review of the literature.Multimodal quantitative MRI assessment of cortical damage in relapsing-remitting multiple sclerosis.The Relationship between Gray Matter Quantitative MRI and Disability in Secondary Progressive Multiple SclerosisLaser Doppler imaging for intraoperative human brain mapping.Contrast-enhanced MR myelography in spontaneous intracranial hypotension: description of an artefact imitating CSF leakage.[Corpus callosum. Landmark of the origin of cerebral diseases].Cerebral gliomas: diffusional kurtosis imaging analysis of microstructural differences.MR imaging of midbrain pathologies.Neuroradiological viewpoint on the diagnostics of space-occupying brain lesions.Differential utilization of ketone bodies by neurons and glioma cell lines: a rationale for ketogenic diet as experimental glioma therapyWhite matter lesions and vascular cognitive impairment: part 1: typical and unusual causes.MR volumetric changes after diagnostic CSF removal in normal pressure hydrocephalus.Spinal cerebrospinal fluid leak as the cause of chronic subdural hematomas in nongeriatric patients.The bioenergetic status relates to dopamine neuron loss in familial PD with PINK1 mutationsPhospholipid metabolites in recurrent glioblastoma: in vivo markers detect different tumor phenotypes before and under antiangiogenic therapyNetrin-1 expression is an independent prognostic factor for poor patient survival in brain metastases.Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma.SMART: physical activity and cerebral metabolism in older people: study protocol for a randomised controlled trial.Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging studyQuantitative MR Imaging of Brain Tissue and Brain Pathologies.Perioperative cerebral ischemia promote infiltrative recurrence in glioblastoma.Central nervous system imaging in childhood Langerhans cell histiocytosis - a reference center analysis.T2-Imaging to Assess Cerebral Oxygen Extraction Fraction in Carotid Occlusive Disease: Influence of Cerebral Autoregulation and Cerebral Blood VolumeMyoinositol as a Biomarker in Recurrent Glioblastoma Treated with Bevacizumab: A 1H-Magnetic Resonance Spectroscopy Study.Advances in neuro-oncology imaging.Differential expression of vascular endothelial growth factor A, its receptors VEGFR-1, -2, and -3 and co-receptors neuropilin-1 and -2 does not predict bevacizumab response in human astrocytomas.Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma.Differential diagnosis of white matter lesions: Nonvascular causes-Part II.Imaging Biomarkers for Adult Medulloblastomas: Genetic Entities May Be Identified by Their MR Imaging Radiophenotype.Therapy of leptomeningeal metastasis in solid tumors.ErbB2/HER2-Specific NK Cells for Targeted Therapy of Glioblastoma.Spectroscopic Characterization of Gliosarcomas-Do They Differ From Glioblastomas and Metastases?Differentiation of neurodegenerative parkinsonian syndromes by volumetric magnetic resonance imaging analysis and support vector machine classification.The tremor network targeted by successful VIM deep brain stimulation in humans.Stripe-like increase of rCBV beyond the visible border of glioblastomas: site of tumor infiltration growing after neurosurgery.Recanalization results after intracranial stenting of atherosclerotic stenoses.MR angiography in patients with subarachnoid hemorrhage: adequate to evaluate vasospasm-induced vascular narrowing?Beyond delayed cerebral vasospasm: infarct patterns in patients with subarachnoid hemorrhage.[Clinical magnetic resonance imaging : Frequent incidental cerebral findings].
P50
Q26853308-94D307EF-8040-4DC4-A995-BAE2369B2E45Q30909859-A3352FD5-3BD4-42A7-9ADD-D30C88BD818BQ31092111-96DDBD6D-6672-4A7A-915D-CB27FCB4ACCCQ31121073-45A8859B-716D-486A-B8D0-FBBB97504749Q33388906-1140C6AA-F56B-4B56-875F-8EEF9708A5A8Q33411815-D3F1BC3D-7639-4F14-AC8D-FD7AEEE94BD3Q33518599-9B3D9B20-D4E3-4716-9F50-064490B82E3AQ33525427-2D8984A5-6BA3-4D28-A56E-8774AAEA3F13Q33598939-05FC8A63-AF49-4C7F-A714-D97E6BEC9040Q33888131-C4480DF8-EAFC-4019-9019-101412E00467Q33972116-0C278010-C324-4633-9178-DFA76BBCB0F5Q34156950-1F4472FD-CAD8-4B4F-90D1-E0ED1E7064A7Q34271844-1C40EA9C-910E-442B-8516-D8EC1788A6FCQ34429622-AFC34160-8A24-47B8-94EA-E85D9F6BF8B1Q34516419-9353CC75-51FD-44D9-95E2-6FDE52B1EE91Q34631627-BBCBBE6D-49F3-4DD7-9F3E-8E66D410AF7AQ35125199-3C2ED86D-7CCD-4693-9649-F34AB2B62266Q35170377-5E427F0C-4B94-4EE7-A62E-47C628F993E4Q35493552-99573156-798F-45BA-A69E-8BE43CC0CF24Q35570253-189E268A-6D17-4B4B-8A5A-17F840492217Q35724467-31CB6377-1FB8-48B9-A9C2-A53B9EE1A89DQ35987408-B1873A69-AB0F-4FDB-A695-27FCA25EC282Q36079249-D052707B-AE5D-4154-B034-5D9333748005Q36112899-F501FDF9-2F8F-4B4E-9EC6-6F82C73E380AQ36235508-0B7C2F82-49FD-429E-92D7-DBB7BA7DD9DEQ36339461-2413F701-6206-42D2-B8FB-C68ABF8D5264Q36493852-EFD9CA69-B09A-455B-9A82-593D3923759DQ37609463-A3C2621A-420D-4536-8544-064A233F9C62Q38187363-F14CAAF7-4B1C-4535-BA2D-ED41A355CCB8Q38629781-B19D46CB-0A5F-4CD1-8B02-2D5C0527C3FDQ38717054-F3173873-4755-4C1D-A8D7-0C875974F987Q38814097-B008DD2B-41D3-4B5D-9EED-4C8A9D4ED7E9Q39454825-C1155A70-9DAB-4314-8E58-0EFDD559EC2AQ39565220-B8569A36-6ADB-43B7-B72F-3D9629FED3BFQ39646506-4EFCB42A-4E44-4BE8-B8F9-87A32110C2E9Q39829938-54089D67-30D3-4895-A11D-972F0B1BF81FQ39907434-650FCEAF-744D-4394-8870-968713A132ADQ39936499-55373591-3656-4DDF-A448-67D18442EB1BQ40064869-B37BDCF8-D1FE-41C5-AEE2-5E50AA940442Q40298678-4A26CD93-2722-47A8-BE84-DBEB09A326E7
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Elke Hattingen
@ast
Elke Hattingen
@en
Elke Hattingen
@es
Elke Hattingen
@nl
Elke Hattingen
@sl
type
label
Elke Hattingen
@ast
Elke Hattingen
@en
Elke Hattingen
@es
Elke Hattingen
@nl
Elke Hattingen
@sl
prefLabel
Elke Hattingen
@ast
Elke Hattingen
@en
Elke Hattingen
@es
Elke Hattingen
@nl
Elke Hattingen
@sl
P214
P244
P106
P21
P214
P244
n2015182509
P31
P4012
P496
0000-0002-8392-9004
P569
2000-01-01T00:00:00Z
P735
P7859
lccn-n2015182509